Usefulness of specific anti‐desmoglein 1 and 3 enzyme‐linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity

Barnadas, M. A.; Rubiales, Ma Victòria; Gich, Ignasi; Gelpí, Carmen

doi:10.1111/ijd.12768

Cited by 9 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While, anti-Dsg-3 antibody level showed no difference during treatment period and anti-Dsg-1 antibody level only presented significant decreasing 6 weeks after treatment. It is inconsistent with other studies, which demonstrated that decrease in anti-Dsg-1 antibody and anti-Dsg-3 antibody level is parallel with the clinical improvement in pemphigus patients ( Barnadas et al, 2015 ). While this inconsistency probably due to the longer follow-up period in other studies.…”

Section: Discussioncontrasting

confidence: 83%

Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity

Lin¹,

Liu²,

Wang³

et al. 2018

PeerJ

View full text Add to dashboard Cite

BackgroundPemphigus is a common life-threatening, autoimmune bullous disease effecting both cutaneous and mucous membranes. Previous diagnosis of pemphigus is based on clinical presentations, histopathology, immunofluorescence and enzyme-linked immunosorbent assay. Furthermore, no laboratory parameters could be used to indicate disease severity. MicroRNAs are endogenous small RNAs, which could be used as diagnostic biomarkers for some autoimmune diseases. Previously, miR-338-3p has been proven significantly up-regulated in pemphigus patients.MethodsPemphigus patients (including pemphigus vulgaris and pemphigus foliaceus) with active lesions and with remission, patients diagnosed as bullous pemphigoid and healthy volunteers were recruited, and miR-338-3p expression level was measured using reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). Active pemphigus patients accepting treatment were followed up for at least 2 weeks to investigate the expression change of miR-338-3p during treatment period. Target genes of miR-338-3p were screened through computer-aided algorithm and verified by RT-qPCR, Western blot and Luciferase activity assay.ResultsMiR-338-3p was specifically increased in patients diagnosed as pemphigus with active lesions. The expression level of miR-338-3p gradually decreased after effective treatment. MiR-338-3p expression was independently correlated with disease severity defined by PDAI (Pemphigus Disease Area Index) or ABSIS (Autoimmune Bullous Skin Disorder Intensity Score) criteria. Up-regulation of miR-338-3p could significantly suppress RNF114 expression at mRNA and protein level in vitro.DiscussionMiR-338-3p could be used as a diagnostic biomarker of pemphigus in addition to other traditional methods. Up-regulation of MiR-338-3p was associated with more severe condition in pemphigus. RNF114 is the target gene of miR-338-3p, which probably participates in the regulation of disease activity of pemphigus.

show abstract

Section: Discussioncontrasting

confidence: 83%

Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity

Lin¹,

Liu²,

Wang³

et al. 2018

PeerJ

View full text Add to dashboard Cite

show abstract

“…The relatively recent development of IIF and ELISA tests have further facilitated the diagnosis of autoimmune bullous dermatoses and comparable sensitivities and specificities have been reported (PV: 75-100%, 91.8-100%; PF: 67-100% for IIF; Dsg3: 81-100%, 94-100%; Dsg1: 69-100%, 61.1-100% for ELISA; Amagai et al, 1999 , Amagai et al, 1999 , Barnadas et al, 2015 , Bracke et al, 2013 , Chiang et al, 2015 , Cozzani et al, 1994 , Daneshpazhooh et al, 2007 , Daneshpazhooh et al, 2014 , Hallaji et al, 2010 , Harman et al, 2000 , Harman et al, 2000 , Ishii et al, 1997 , Jiao and Bystryn, 1997 , Khandpur et al, 2010 , Mortazavi et al, 2015 , Schmidt et al, 2010 , Sharma et al, 2006 , Tampoia et al, 2012 , van Beek et al, 2012 , van Beek et al, 2017 , Zagorodniuk et al, 2005 ). An international, multicenter study further demonstrated a high diagnostic agreement of 93.6% (Cohen k value, 0.95) between DIF results and multivariant ELISA testing for patients with pemphigus ( van Beek et al, 2017 ).…”

Section: Discussionmentioning

confidence: 91%

“…Furthermore, Barnadas et al (2015) reported inaccuracies in anti-Dsg1 and Dsg3 ELISA values when titer levels exceeded 150 U/mL, which is possibly due to the saturation of the system and results in artefactually low scores. Additionally, later studies have demonstrated that a semi-quantitative analysis can be achieved.…”

Section: Discussionmentioning

confidence: 99%

New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature

Xuan

Yang

Murrell

2018

International Journal of Women's Dermatology

View full text Add to dashboard Cite

The immunoassays that are available for the serological diagnosis of the more common subtypes of autoimmune blistering diseases such as pemphigus vulgaris (PV) and pemphigus foliaceus (PF) include enzyme-linked immunosorbent assay (ELISA) testing to specific antigens desmoglein (Dsg)1 and Dsg3, direct immunofluorescence (DIF), indirect immunofluorescence (IIF), and immunoblotting. A review of the literature on the biochip assay was conducted. Six studies investigated the validity of a new biochip, mosaic-based, IIF test in patients with pemphigus and demonstrated its relatively high sensitivity and specificity (Dsg3: 97.62-100%, 99.6-100%; Dsg1: 90%, 100%) in comparison with ELISA (Dsg3: 81-100%, 94-100%; Dsg1: 69-100%, 61.1-100%), and/or IIF (PV: 75-100%, 91.8-100%; PF: 67-100%) using suitable substrates. So far, validation studies of the biochip have been conducted in four countries (Germany, Italy, Turkey, and Poland) but none in the southern hemisphere. Caucasian patients were recruited as normal controls for these studies; thus, the diagnostic value of the biochip remains uncertain in population groups of other ethnicities. A range of disease control patients were recruited including patients with linear immunoglobulin A dermatosis, psoriasis, discoid lupus erythematosus, lichen planus, and noninflammatory skin diseases (e.g., squamous cell carcinoma, basal cell carcinoma, and vascular leg ulcers). Prospective studies with control patients from a diverse range of ethnicities are needed to better validate the biochip.

show abstract

“…Indirect immunofluorescence Autoimmune Bullous Diseases(IIF) examination, using a substrate of normal human skin or monkey esophagus, shows circulating antiepithelial IgG and lace-like deposition [2,4,5,12]. Enzyme-linked immunosorbent assay (ELISA) is also available in detecting antigens of PV and serves as a tool for assessing the disease severity [44,45]. Target antigens identified in PV are Dsg1 (with a molecular weight (MW) of 165 kD) and Dsg3 (MW-130 kD) [2][3][4][5]9].…”

Section: Immunopathology and Target Antigensmentioning

confidence: 99%

Pemphigus: Subtypes, Clinical Features, Diagnosis, and Treatment

Kılıç¹

2018

Autoimmune Bullous Diseases

View full text Add to dashboard Cite

Pemphigus is a group of autoimmune blistering disorders associated with autoantibodies against the keratinocyte cell surface. Pemphigus has three major variants: pemphigus vulgaris (PV), pemphigus foliaceus (PF), and paraneoplastic pemphigus (PNP) which all have further subtypes. The variants of pemphigus are classified depending upon the clinical and histological features, immunofluorescence staining pattern, and autoantibody profile of the disease. The onset and course of pemphigus appear on the basis of interaction between genetic predisposition and various triggering factors. Pemphigus vulgaris is the most commonly seen and representative clinical form of pemphigus. Together with clinical manifestations, the histopathological and immunopathological data support the diagnosis. As though some pemphigus variants, particularly pemphigus vulgaris and paraneoplastic pemphigus, have a mortality risk, early diagnosis is necessary and onset of treatment should be promptly initiated. In this chapter, firstly, classification of pemphigus is described. After then, clinical features, histopathological and immunopathological findings, target antigens, etiopathogenesis and comorbidities of each pemphigus variant are discussed briefly.Keywords: pemphigus, pemphigus variants, clinical manifestations, pathogenesis, histopathology, immunopathology IntroductionPemphigus is a distinct organ-specific autoimmune blistering disorder involving skin and mucous membranes associated with autoantibodies directed against desmosomes-intercellular adhesive molecule complex localized on the keratinocyte cell surface [1][2][3][4].© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Pemphigus has three major variants, which are classified depending on the basis of the clinical, histological features, immunofluorescence staining pattern and autoantibody profile of the disease including pemphigus vulgaris (PV), pemphigus foliaceus (PF), and paraneoplastic pemphigus (PNP), which all have further subtypes. Less frequently seen and newer variants of pemphigus include IgA pemphigus (IGAP) and pemphigus herpetiformis (PH) [1-6].The term "pemphigus" origins from the Greek word "pemphix", which has a meaning of "blister" [1]. It is a chronic potentially life-threating bullous disorder if not treated on time [4,7,8]. The phenotypes of pemphigus represent a complex spectrum with multiple genetic and environmental factors playing a role in disease pathogenesis [9,10].Together with clinical manifestations, the histopathological and immunopathological data support the diagnosis of the disease. The best site for the cutaneous biopsy for the appropriate histopathological examination is a fresh (< 24 h) small vesicle or 1/3 of the peripheral portion of the blister including the perilesional normal appearing s...

show abstract

Usefulness of specific anti‐desmoglein 1 and 3 enzyme‐linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity

Abstract: Therapeutic strategies should not be based exclusively on anti-Dsg antibody values. Anti-Dsg1 antibodies showed a closer relationship with skin activity than IIF, while anti-Dsg3 antibodies showed a relationship with mucosal activity similar to the IIF test.

Cited by 9 publications

References 30 publications

Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity

Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity

New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature

Pemphigus: Subtypes, Clinical Features, Diagnosis, and Treatment

Contact Info

Product

Resources

About